Friederike Holze
PhD, Post-Doc at Psychopharmacology Research group of Prof. M. Liechti
at University of Basel
Abstract:
Classic psychedelics such as lysergic acid diethylamide (LSD) and psilocybin are back in research as potential treatment for various psychiatric and somatic disorders, e.g. depression, anxiety disorders and cluster headache. Modern experimental studies with psilocybin-assisted therapy for anxiety and depression show promising results. However, there are remaining questions regarding the distinction of psychedelics to stimulants and entactogens, the definition and characterization of microdoses and psychedelic doses, and dose equivalence of psilocybin and LSD. This talk covers data from four recent double-blind, randomized, placebo-controlled, crossover trials in healthy volunteers. Findings are important for dose finding of LSD and the choice of substance in future research for substance- assisted therapy.
Bio:
Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.